Login to Your Account



XBiotech's 'True Human' Antibody Xilonix Hits the Spot for Cachexia

By Anette Breindl
Science Editor

Thursday, October 4, 2012
in_the_clinic.jpg

Austin-based XBiotech Inc. is launching its first Phase III trial, for its antibody Xilonix (MABp1), after announcing Wednesday that the monoclonal antibody received fast-track designation by the FDA.

Xilonix will be tested for the treatment of cachexia, a wasting syndrome that can occur with cancer as well as other chronic diseases. In the Phase II trial that was the basis of the fast-track designation, about a third of patients responded to the antibody. And those that did not only started building muscle, but had increased survival as well.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription